Greenlight Capital Teva Pharma Industries Ltd ADR transactions over time
TEVA-OLD
Teva Pharma Industries Ltd ADR historical holders
total: 10
Transactions details
- Total transactions:
- 8
- New positions:
- 1
- Added:
- 4
- Reduced:
- 3
- Held since:
- 2023 Q4
- Held for:
- 11 quarters
- Latest activity:
- 2026 Q2
David Einhorn has been an institutional investor in Teva Pharma Industries Ltd ADR (TEVA-OLD) since 2023 Q4. According to 2026 Q2 report, David Einhorn holds 2,886,059 shares with a market value of roughly $97.78M representing 2.50% of their equity portfolio. The fund/company first acquired TEVA-OLD in 2023 Q4, initially purchasing 268,470 shares. Since the initial investment, Greenlight Capital has made 7 more transactions in this position.
Does David Einhorn still hold TEVA-OLD?
Yes, David Einhorn continues to hold Teva Pharma Industries Ltd ADR (TEVA-OLD). According to their 2026 Q2 report, they maintain a position of 2,886,059 shares valued at approximately $97.78M, representing 2.50% of their equity portfolio.
When did David Einhorn first invest in TEVA-OLD?
David Einhorn first invested in Teva Pharma Industries Ltd ADR (TEVA-OLD) in 2023 Q4 at the reported quarter-end price of $10.44 per share, acquiring 268,470 shares in their initial purchase.
What is David Einhorn's average cost basis for TEVA-OLD?
Based on historical transaction data, David Einhorn's estimated cost basis for Teva Pharma Industries Ltd ADR (TEVA-OLD) is approximately $16.44 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $16.44
- Weighted AVG sell price:
- $31.10
TEVA-OLD transactions history by Greenlight Capital
8 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2026 Q2
|
2.50%
|
2,886,059
|
$33.88
|
$97,779,679
|
-0.85% (-24,670)
|
-0.03%
|
|
2026 Q1
|
2.75%
|
2,910,729
|
$30.12
|
$87,671,158
|
-4.84% (-148,005)
|
-0.16%
|
|
2025 Q4
|
3.35%
|
3,058,734
|
$31.21
|
$95,463,088
|
-19.05% (-720,043)
|
-0.88%
|
|
2025 Q2
|
2.72%
|
3,778,777
|
$16.76
|
$63,332,302
|
+565.04% (+3,210,577)
|
+2.31%
|
|
2025 Q1
|
0.44%
|
568,200
|
$15.37
|
$8,733,234
|
+21.27% (+99,650)
|
+0.08%
|
|
2024 Q4
|
0.53%
|
468,550
|
$22.04
|
$10,326,842
|
+44.24% (+143,700)
|
+0.16%
|
|
2024 Q1
|
0.21%
|
324,850
|
$14.11
|
$4,583,634
|
+21.00% (+56,380)
|
+0.04%
|
|
2023 Q4
|
0.14%
|
268,470
|
$10.44
|
$2,802,826
|
new
|
+0.14%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.